Floatz logo

EF-5

Adult Grade II Meningioma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Adult Grade II Meningioma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Essen Biotech
Phase 2B
Fludarabine
Essen Biotech
Phase 2B
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Anti-Ny Eso-1 Mtcr Pbl
National Cancer Institute (NCI)
Phase 2B

View all 19 →

Same molecule, other indications

EF-5 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
Stage I Ovarian Epithelial CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →